0000000000371010

AUTHOR

Karl Walravens

showing 2 related works from this author

An assessment of prime‐boost vaccination schedules with AS03A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults

2012

Please cite this paper as: Gillard et al. (2012) An assessment of prime‐boost vaccination schedules with AS03A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2012.00349.x. Background  Long‐term persistence of immune response and safety of an H5N1 prepandemic influenza vaccine adjuvanted with AS03 (an α‐tocopherol oil‐in‐water emulsion‐based adjuvant system) was evaluated using various prime‐boost schedules that mimicked potential pandemic scenarios (NCT00430521). Methods  Five hundred and twelve healthy adults aged 18–60 years received primary vaccination with one or two doses (0, 21 days schedule…

AdultMaleAdolescentalpha-TocopherolImmunization SecondaryAntibodies ViralAS03Young Adultprime‐boostAdjuvants ImmunologicInfluenza HumanHumansAdjuvantImmunization ScheduleInfluenza A Virus H5N1 SubtypeVaccinationOriginal ArticlesH5N1Hemagglutination Inhibition TestsMiddle AgedAntibodies NeutralizingTreatment OutcomeInfluenza VaccinesOriginal ArticleFemaleinfluenzaprepandemicInfluenza and Other Respiratory Viruses
researchProduct

An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults

2012

Please cite this paper as: Gillard et al. (2012) An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750-2659.2012.00349.x. Background  Long-term persistence of immune response and safety of an H5N1 prepandemic influenza vaccine adjuvanted with AS03 (an α-tocopherol oil-in-water emulsion-based adjuvant system) was evaluated using various prime-boost schedules that mimicked potential pandemic scenarios (NCT00430521). Methods  Five hundred and twelve healthy adults aged 18–60 years received primary vaccination with one or two doses (0, 21 days schedule…

Pulmonary and Respiratory MedicineHeterologous vaccineH5N1 vaccineEpidemiologybusiness.industryInfluenza vaccineImmunogenicitymedicine.medical_treatmentPublic Health Environmental and Occupational HealthBooster doseVirologyVaccinationInfectious DiseasesImmunologyMedicineAS03businessAdjuvantInfluenza and Other Respiratory Viruses
researchProduct